2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 858

Identification of Clinically Relevant Pain Profiles in Individuals with Active RA
Abstract Number: 181

Identification of Disease-Susceptible Lncrna Contributed to Abnormal Activation of Type I Interferon Pathway in Systemic Lupus Erythematosus
Abstract Number: 674

Identification of IRAK4-Dependent Gene Signature As a Biomarker Candidate for IRAK4 Small-Molecule Inhibitor in Systemic Lupus Erythematosus
Abstract Number: 1334

Identification of Key Regulators for Resolution of Chronic Inflammatory Arthritis through a Systems Approach
Abstract Number: 984

Identification of Key Screening Characteristics for Systemic Lupus Erythematosus Natural History
Abstract Number: 1659

Identification of Long Noncoding RNA RP11-2B6.2 As a Positive Regulator through Type I Interferon Pathway in Lupus Nephritis
Abstract Number: 2125

Identification of Long-Term Prognostic Factors for Relapse or Exacerbation in Patients with Pulmonary Sarcoidosis: A Single Center Long-Term Observational Cohort Study
Abstract Number: 2134

Identification of Multiple Cancer Associated Myositis Specific Antibodies in Idiopathic Inflammatory Myopathies: A Large Longitudinal Cohort Study
Abstract Number: 950

Identification of Naturally Processed Immunodominant Topoisomerase I Epitopes in Patients with Systemic Sclerosis
Abstract Number: 168

Identification of Novel Susceptibility Loci in a Large UK Cohort of Juvenile Idiopathic Arthritis (JIA) Cases
Abstract Number: 2270

Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis
Abstract Number: 2976

Identification of Systemic Lupus Erythematosus Causal Risk Variant Candidates Spanning the UBE2L3 Haplotype
Abstract Number: 2057

Identification of Urate Deposits in Patients with Asymptomatic Hyperuricemia Using a Dual-Energy CT Scan
Abstract Number: 2

Identifying “Second Hit” Risk Factor(s) Associated with Thrombosis and Pregnancy Morbidity in Ethnically Diverse Antiphospholipid Antibodies Positive Patients
Abstract Number: 983

Identifying Exposures to Chemicals in Patients with SLE – a Non-Targeted Exposome Approach Reveals Enrichment for Phthalates

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].